| Value | ₹3.87 Cr |
|---|
NSE filing, NSE: AJOONI. Summary written from the filing by ALFA Finder's alert engine.
Ajooni Biotech Ltd: key numbers
- Share price
- ₹2.94
- Market cap
- ₹50.64 Cr
- Revenue (annual)
- ₹182.4 Cr
- Net profit (annual)
- ₹4.32 Cr
- P/E (TTM)
- 12.8×Sector 26.2×
- Promoter holding
- 30.53%+3.64% QoQ
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Ajooni Biotech Ltd
All →Ajooni Biotech Other Announcement
Ajooni Biotech informed NSE that its website is updated and functional per Reg 46 of SEBI LODR. This is a routine compliance intimation with no business or financial substance.
Ajooni Biotech Q1 FY27 Results: Net Profit ₹0.4 Cr, Down 50.0% YoY
Ajooni Biotech Ltd reported revenue from operations of ₹63.5 Cr (+102.9% YoY) and net profit of ₹0.4 Cr (-50.0% YoY) for Q1 FY27.
- Key figure
- Net profit ₹0.4 Cr · -50.0% YoY
Ajooni Biotech Capital Structure Change
Ajooni Biotech has allotted 90 lakh equity shares to Healthy Biosciences Limited. The total issue value is ₹3.87 Crore.
- Value
- ₹3.87 Cr
Ajooni Biotech Board Meeting Date
Ajooni Biotech Limited has scheduled a board meeting for August 14, 2026. The board will consider and approve unaudited standalone financial results for the June 2026 quarter.
Ajooni Biotech Capital Structure Change
The company's shareholders approved an increase in its authorized share capital to ₹70 Crore at the 16th Annual General Meeting.
Ajooni Biotech Capital Structure Change
Ajooni Biotech received shareholder approval for the preferential issuance of 90,00,000 equity shares at Rs. 4.30 each, valued at approximately ₹3.87 Crore.
- Value
- ₹3.87 Cr
Other board meeting outcome announcements
All →R R Kabel Board Meeting Outcome
RR Kabel's board approved amendments to its UPSI fair disclosure code on 28 October 2026. The amended code is enclosed and posted on the company website.
M K Exim (India) Board Meeting Outcome
M.K. Exim (India) approved shifting its registered office within Jaipur to Plot J-1247, Sitapura. The board meeting was held on October 28, 2026.
United Spirits Board Meeting Outcome
United Spirits' board approved amendments to its insider trading code on 28 October 2026, effective 29 October 2026. The revised code is available on the company website.
SBI Funds Management Board Meeting Outcome
SBI Funds Management extended internal auditor Chhajed & Doshi's term to March 31, 2030. This routine decision was taken at the October 28, 2026 board meeting.
- Execution
- April 1, 2028 to March 31, 2030
Paras Healthcare Board Meeting Outcome
Paras Healthcare filed its board-approved UPSI fair disclosure code under Regulation 8(2). This routine governance policy update reports no business event.
Gateway Distriparks Board Meeting Outcome
Gateway Distriparks' board approved a revised Code of Practices for Fair Disclosure of UPSI under PIT Regulation 8(2). This is a routine governance policy update with no business event.